Molecular-Lab Radiopharmaceutical Synthesis System

描述(申请人提供)：这项工作的长期目标是促进放射化学的基础研究和临床前应用，以便更好地了解综合性癌症中心的反应评估、分子和生理图谱、细胞跟踪和细胞表面靶向。所要求的仪器将允许有效地生产用于临床前研究的各种氟-18标记放射性示踪剂。这些将利用莫菲特公司在成像研究方面已经投入的大量资金，其中包括最近在回旋加速器附近建造的一个研究性放射化学实验室。优先考虑对8个主要用户最感兴趣的示踪剂，这些用户现有的NIH支持的项目研究癌症的新治疗靶点或治疗反应生物标记物。在使用初期，该系统将产生18F-FAC、18F-FHBG和18F-FMAU，因为这些放射性示踪剂以前是在模块化实验室系统上合成的，并且有规格表可用。在QA/QC和仪器签字后，将采用两条多肽放射性标记路线：18F-NPFP标记RGD(Arg-Gly-Asp)；18F-SFB标记PHLIP(pH低插入多肽)、MTI-101(内部开发以结合HYD-1)和MTI-T02(内部开发以结合TLR-2)。之后，将探索18F Nifene(结合尼古丁受体)、[18F]-Fasu(Glu/Cys转运蛋白SLC7A11的底物)和18F-CMD(吲哚胺双加氧酶底物)。由于要在有限的空间内制造这些示踪剂的种类和数量，需要一种占地面积小的机器人合成系统。该仪器将作为小动物成像核心设施内的一项共享服务进行管理，该设施将负责制定充电率。主要用户计划获得10个R01、1个U10、1个U54、1个P01和1个P50资助。该机构为该企业提供长期支持，除该设施的运营预算外，还将支付年度维护协议的费用。在资源允许的情况下，将支持更多的示踪剂和开发项目，并将扩大支持和教育，使更广泛的研究和护理社区受益。这些示踪剂将使癌症患者对他们的疾病有更好的、个性化的了解，并从改善对治疗效果的监测和预测中受益。

DESCRIPTION (provided by applicant): The long-term objective of this work is to contribute to basic research and pre-clinical applications of radiochemistry for better understanding of response assessment, molecular and physiological profiling, cell tracking and cell surface targeting in a comprehensive cancer center. The requested instrument will allow the efficient production of an assortment of fluorine-18 labeled radiotracers for pre-clinical investigations. These will leverage an already substantial investment of the Moffitt into imaging research, which has recently included the build out of a research radiochemistry laboratory adjacent to the cyclotron. Priority is assigned to tracers of highest interest to 8 major users with existing NIH supported programs that investigate novel therapeutic targets, or therapy response biomarkers in cancer. In the initial period of use, 18F-FAC; 18F-FHBG and 18F-FMAU will be generated with this system, as these radiotracers have previously been synthesized on the Modular Lab system and spec sheets are available. Following QA/QC and signoff of the instrument, two routes for peptide radiolabeling will be pursued: 18F-NPFP for RGD (Arg-Gly-Asp); and 18F-SFB to label pHLIP (pH low insertion peptide), MTI-101 (developed in house to bind Hyd-1), and MTI-T02 (developed in house to bind TLR-2). After these, there are plans to pursue 18F Nifene (binds Nicotinic ¿4¿2 receptor), [18F] - FASu (substrate for Glu/Cys transporter SLC7A11) and 18F-CMD (substrate for indoleamine di-oxygenase, IDO) will be explored. Because of the variety and number of these tracers to be made within limited space, a small footprint robotic synthesis system is needed. The instrument will be managed as a shared service within the Small Animal Imaging core facility, which will be responsible for establishing recharge rates. Major user programs are supported by 10 R01, 1 U10, 1 U54, 1 P01 and 1 P50 grant. Long term support for this enterprise is provided by the Institution, which will cover the costs of the annual maintenance agreement apart from the facility's operating budget. Additional tracers, and developing programs will be supported as resources permit, and support and education will be extended to benefit the wider research and care community. These tracers will benefit cancer patients with improved, personalized knowledge of their disease, and from improved monitoring and prediction of treatment effects.